ReviewFrontiers in medicine2026
The use of MRI in the diagnosis of ovarian cancer.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a malignant tumor of the female reproductive system with a high mortality rate. Currently, China has the highest number of new ovarian cancer cases worldwide; therefore, preoperative diagnosis is of particular importance. Magnetic resonance imaging (MRI), with its excellent soft tissue resolution and absence of ionizing radiation risk, has become a key imaging modality for the non-invasive diagnosis of ovarian cancer in clinical practice. This article systematically reviews the latest research advances in the application of conventional morphological MRI, multiparametric MRI, and the integration of MRI with radiomics and deep learning technologies in the diagnosis and treatment of ovarian cancer. It focuses on their clinical value in assessing the benign or malignant nature of ovarian tumors, classifying pathological subtypes of epithelial and non-epithelial ovarian cancers, staging ovarian cancer, monitoring treatment efficacy, and predicting prognosis. Additionally, it outlines research directions for emerging technologies such as molecular probes. Existing studies have confirmed that multimodal MRI fusion technology can significantly improve the diagnostic accuracy of ovarian cancer; however, challenges remain, including a lack of model generalizability, insufficient interpretability, difficulty in detecting micro-lesions, and low clinical adoption rates. Future efforts should focus on establishing standardized MRI scanning protocols and data standards, conducting large-scale, multicenter prospective studies, deepening the integrated application of interpretable artificial intelligence and molecular imaging, and constructing an integrated "imaging-biology-clinical" precision assessment system to advance the development of precision preoperative diagnosis and treatment for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.